Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Mar;45(3):395–402. doi: 10.1038/bjc.1982.67

Characterization of a monoclonal antibody to L1210 leukaemia.

C Testorelli, S Morelli, A Goldin, A Nicolin
PMCID: PMC2010931  PMID: 7073934

Abstract

A mouse of monoclonal cell line (L1) was produced by fusing the mouse myeloma P3X63/Ag8 with CD2F1 spleen cells immunized with a highly immunogenic subline of L1210 leukaemia (L1210/DTIC). A very few positive clones (1%) were isolated and one of these was chosen for detailed study. The monoclonal antibody L1 is an IgM immunoglobulin strongly reacting in a complement-dependent cytotoxicity assay against L1210/Cr leukaemia and its more or less immunogenic sublines. The specificity of the L1 antibody against L1210 leukaemia was studied by extensive screening with normal adult and foetal tissues, lymphoid tissues from several independent strains and a panel of the most common experimental tumours, to all of which it was unreactive. Attempts at immunotherapy were carried out in DBA/2 mice challenged with L1210 leukaemia and treated with L1 (ascites) and complement. Although the in vitro cytotoxic titre of ascites fluid from mice bearing hybridoma was very high (10(-7)), no therapeutic effect was obtained in vivo.

Full text

PDF
402

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abelson H. T., Rabstein L. S. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 1970 Aug;30(8):2213–2222. [PubMed] [Google Scholar]
  2. Black P. H. Shedding from normal and cancer-cell surfaces. N Engl J Med. 1980 Dec 11;303(24):1415–1416. doi: 10.1056/NEJM198012113032411. [DOI] [PubMed] [Google Scholar]
  3. Bonmassar E., Bonmassar A., Vadlamudi S., Goldin A. Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Natl Acad Sci U S A. 1970 Aug;66(4):1089–1095. doi: 10.1073/pnas.66.4.1089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boyse E. A., Stockert E., Old L. J. Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A. 1967 Sep;58(3):954–957. doi: 10.1073/pnas.58.3.954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cerottini J. C., Engers H. D., Macdonald H. R., Brunner T. Generation of cytotoxic T lymphocytes in vitro. I. Response of normal and immune mouse spleen cells in mixed leukocyte cultures. J Exp Med. 1974 Sep 1;140(3):703–717. doi: 10.1084/jem.140.3.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cooper S. M., Sambray Y., Frious G. J. Isolation of separate Fc receptors for IgG complexed to antigen and native IgG from a murine leukaemia. Nature. 1977 Nov 17;270(5634):253–255. doi: 10.1038/270253a0. [DOI] [PubMed] [Google Scholar]
  7. Gunn B., Embleton M. J., Middle J. G., Baldwin R. W. Monoclonal antibody against a naturally occurring rat mammary carcinoma. Int J Cancer. 1980 Sep 15;26(3):325–330. doi: 10.1002/ijc.2910260311. [DOI] [PubMed] [Google Scholar]
  8. Hewitt H. B., Blake E. R., Walder A. S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976 Mar;33(3):241–259. doi: 10.1038/bjc.1976.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Houston L. L., Nowinski R. C., Bernstein I. D. Specific in vivo localization of monoclonal antibodies directed against the Thy 1.1 antigen. J Immunol. 1980 Aug;125(2):837–843. [PubMed] [Google Scholar]
  10. KLEIN G., SJOGREN H. O., KLEIN E., HELLSTROM K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960 Dec;20:1561–1572. [PubMed] [Google Scholar]
  11. Kitano M., Mihich E., Pressman D. Antigenic differences between leukemia L1210 and a subline resistant to methylglyoxal-bis(guanylhydrazone). Cancer Res. 1972 Feb;32(2):181–186. [PubMed] [Google Scholar]
  12. LITTLEFIELD J. W. SELECTION OF HYBRIDS FROM MATINGS OF FIBROBLASTS IN VITRO AND THEIR PRESUMED RECOMBINANTS. Science. 1964 Aug 14;145(3633):709–710. doi: 10.1126/science.145.3633.709. [DOI] [PubMed] [Google Scholar]
  13. Mihich E., Kitano M. Differences in the immunogenicity of leukemia L1210 sublines in DBA-2 mice. Cancer Res. 1971 Dec;31(12):1999–2003. [PubMed] [Google Scholar]
  14. Motta R. Passive immunotherapy of leukemia and other cancer. Adv Cancer Res. 1971;14:161–179. doi: 10.1016/s0065-230x(08)60520-5. [DOI] [PubMed] [Google Scholar]
  15. Nadler L. M., Stashenko P., Hardy R., Kaplan W. D., Button L. N., Kufe D. W., Antman K. H., Schlossman S. F. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980 Sep;40(9):3147–3154. [PubMed] [Google Scholar]
  16. Nadler L. M., Stashenko P., Hardy R., Schlossman S. F. A monoclonal antibody defining a lymphoma-associated antigen in man. J Immunol. 1980 Aug;125(2):570–577. [PubMed] [Google Scholar]
  17. Nicolin A., Bini A., Coronetti E., Goldin A. Cellular immune response to a drug-treated L5178Y lymphoma subline. Nature. 1974 Oct 18;251(5476):654–655. doi: 10.1038/251654a0. [DOI] [PubMed] [Google Scholar]
  18. Nowinski R. C., Lostrom M. E., Tam M. R., Stone M. R., Burnette W. N. The isolation of hybrid cell lines producing monoclonal antibodies against the p15(E) protein of ecotropic murine leukemia viruses. Virology. 1979 Feb;93(1):111–126. doi: 10.1016/0042-6822(79)90280-0. [DOI] [PubMed] [Google Scholar]
  19. OLD L. J., BOYSE E. A. IMMUNOLOGY OF EXPERIMENTAL TUMORS. Annu Rev Med. 1964;15:167–186. doi: 10.1146/annurev.me.15.020164.001123. [DOI] [PubMed] [Google Scholar]
  20. Ozato K., Mayer N., Sachs D. H. Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. J Immunol. 1980 Feb;124(2):533–540. [PubMed] [Google Scholar]
  21. PREHN R. T., MAIN J. M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed] [Google Scholar]
  22. Ritz J., Pesando J. M., Notis-McConarty J., Lazarus H., Schlossman S. F. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature. 1980 Feb 7;283(5747):583–585. doi: 10.1038/283583a0. [DOI] [PubMed] [Google Scholar]
  23. Rosenberg S. A., Terry W. D. Passive immunotherapy of cancer in animals and man. Adv Cancer Res. 1977;25:323–388. doi: 10.1016/s0065-230x(08)60637-5. [DOI] [PubMed] [Google Scholar]
  24. Shevach E. M., Stobo J. D., Green I. Immunoglobulin and theta-bearing murine leukemias and lymphomas. J Immunol. 1972 May;108(5):1146–1151. [PubMed] [Google Scholar]
  25. Stackpole C. W., Cremona P., Leonard C., Stremmel P. Antigenic modulation as a mechanism for tumor escape from immune destruction: identification of modulation-positive and modulation-negative mouse lymphomas with xenoantisera to murine leukemia virus gp70. J Immunol. 1980 Oct;125(4):1715–1723. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES